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Abstract
The triplet combination of irinotecan, oxaliplatin and fluorouracil is an active frontline
regimen in metastatic colorectal cancer, but scarce data exist on its use as salvage
treatment. We aimed at assessing its safety and efficacy profiles with its circadian-
based administration (chronoIFLO5) as either first- or second-line treatment, within
the time-finding EORTC 05011 trial. Five-day chronoIFLO5 was administered every
3 weeks in patients with PS 0, 1 or 2. It consisted of chronomodulated irinotecan
(180 mg/sqm), oxaliplatin (80 mg/sqm) and fluorouracil-leucovorin (2800 and
1200 mg/sqm, respectively). For our study, toxicity and antitumour activity were
Abbreviations: chronoIFLO5, chronomodulated irinotecan, fluorouracil, leucovorin, oxaliplatin over 5 days; EGFR, epithelial growth factor receptor; EORTC, European Organisation for Research
and Treatment of Cancer; FOLFIRINOX, irinotecan, fluorouracil, leucovorin, oxaliplatin; FOLFOXIRI, folinic acid, 5-fluorouracil, oxaliplatin and irinotecan; G-CSF, granulocyte colony-stimulating
factor; GI, gastrointestinal; NCI CTC AE, National Cancer Institute Common Terminology Criteria for Adverse Events; ORR, objective response rate; OS, overall survival; PFS, progression-free
survival; PS, performance status; RECIST, Response Evaluation Criteria in Solid Tumours; sqm, square metre; VEGF, vascular endothelial growth factor.
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evaluated separately in first- and second-line settings. Primary endpoints included
Grade 3-4 toxicity rates, best objective response rate (ORR), progression-free survival
(PFS) and overall survival (OS). One-hundred forty-nine and 44 patients were treated
in first-line and second-line settings, respectively, with a total of 1138 cycles with
median relative dose intensities of about 90%. Demographics were comparable in the
two groups. Thirty-six (24.7%) and 10 (22.2%) patients experienced at least one epi-
sode of severe toxicity in first line and second line, respectively. Frontline
chronoIFLO5 yielded an ORR of 62.3% [95% CI: 54.2-70.4] and resulted in median
PFS and OS of 8.7 months [7.5-9.9] and 19.9 months [15.4-24.5]. Corresponding fig-
ures in second line were 37.5% [22.5-52.5], 6.7 months [4.8-8.9] and 16.3 months
[11.8-20.8]. International and prospective evaluation revealed the favourable safety
and efficacy profiles of chronoIFLO5, both as frontline and as salvage treatment
against metastatic colorectal cancer. In particular, encouraging activity in second line
was observed, with limited haematological toxicity.
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1 | BACKGROUND
Colorectal cancer is the second most common neoplastic disease
across Europe in terms of both incidence and mortality.1 Systemic
chemotherapy is the principal therapeutic option for metastatic dis-
ease, and it is best tailored to patient's and disease's features within a
multidisciplinary oncosurgical strategy.2 One such approach is to
intensify chemotherapy with the aim of obtaining substantial down-
sizing to allow conversion from nonresectable to resectable disease.3
The combination of the three main cytotoxic drugs active against
colorectal cancer, 5-fluorouracil, oxaliplatin and irinotecan, constitutes
the chemotherapy backbone, which has achieved the best outcomes
in the metastatic setting.4,5 Nonetheless, the triplet regimen has also
been associated with worse toxicity in comparison with doublets.6
Hence, better patient outcomes could be expected with the improved
tolerability of the triplet regimen.
The administration of each chemotherapy drug at a defined time
based on its circadian tolerability constitutes the rationale of chrono-
therapy.7-9 Indeed, the chronomodulated triplet has demonstrated
satisfactory safety and efficacy in monocentric studies in patients
with metastatic colorectal cancer.10-13 Based on this evidence, we
conducted an international time-finding study (EORTC 05011) to
identify the least toxic administration time of Irinotecan, combined
with chronomodulated oxaliplatin and 5-fluorouracil + leucovorin.14
This trial failed to meet its primary endpoint of determining the time
of irinotecan delivery causing the lowest toxicity in the whole popu-
lation.14 Nevertheless, in accordance with recent evidence of the
impact of gender in outcomes of chemotherapy against colorectal
cancer, we found a lag in the least toxic time of irinotecan adminis-
tration according to gender. Thus, lower toxicity of irinotecan was
highlighted following dosing in the early morning for men and in the
afternoon for women.14
Here, we performed a final update of the EORTC 05011 trial
data, which complements overall safety and efficacy of chro-
nomodulated triplet both in the first-line setting, comparatively to
existing data with conventional administration, and as a second-line
regimen, for which scant prospective multicentric data exist.
2 | METHODS
2.1 | Study population
The EORTC 05011 trial involved 18 institutions in Europe, which
enrolled a total of 199 adult patients with histologically proven,
measurable and unresectable advanced colorectal cancer and good
What's new?
Triple chemotherapy of irinotecan, oxaliplatin and
fluorouracil-leucovorin achieves the best survival against
metastatic colorectal cancer (CRC) but has worse toxicity
than doublet therapy. Chronomodulation is a strategy to
reduced toxicity by coordinating drug administration with
the patient's circadian rhythm. Here, the authors evaluated
the safety and efficacy of chronomodulated triple therapy
given over a 5-day period every 3 weeks. 149 patients
received the treatment as a first-line regimen, while
44 received it as salvage therapy. In both settings, the safety
and efficacy of chronomodulated triple therapy were vali-
dated, although the optimal timing of irinotecan for minimiz-
ing toxicity remains to be determined.
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(ie, <3 on the World Health Organisation scale) performance status,
between February 2002 and August 2005. Patients could have
received up to one prior line of chemotherapy for metastatic dis-
ease or locoregional recurrence, including irinotecan- or oxaliplatin-
based combination protocols. Adjuvant chemotherapy was consid-
ered as first line, if relapse occurred within 6 months of its comple-
tion. Patients were required to have adequate hepatic, renal and
haematological functions, no baseline diarrhoea >Grade 1 (NCIC
CTCAE v2) and no prior toxicity related to irinotecan ≥Grade
3. Patients with uncontrolled medical conditions or psychosocial
issues representing a potential risk for study compliance and for
patient's safety were excluded. The main endpoint of the study was
to identify the least toxic time of administration of irinotecan, and
patients were randomised to one of six possible times; details on
the sample size calculation and allocation to the six treatment arms
are provided elsewhere.14 Specifically, 193 patients out of the
199 randomised ones (97%) were considered eligible for tolerability
and efficacy evaluation: 149 patients were treated in the first-line
setting and 44 in the second-line one (Figure 1). The trial was
approved by the respective ethics review boards at each centre
and/or country. It was conducted in accordance with the Declara-
tion of Helsinki guidelines for experimentation on humans.15
Signed informed consent was obtained from every participating
patient.
2.2 | Chemotherapy schedule
Chrono-IFLO5 consisted of the association of irinotecan, adminis-
tered as a 6-hour chronomodulated infusion with peak delivery times
scheduled every 4 hours according to the allocated treatment arm,
followed by the chronomodulated combination of fractionated and
alternating 5-fluorouracil-leucovorin, peaking at 04:00 AM at night,
and oxaliplatin, peaking at 4:00 PM, each over 11.5 hours per day for
4 consecutive days (Figure 2). Respective starting doses were
180 mg/sqm for irinotecan, 700 mg/sqm/day for 5-fluorouracil,F IGURE 1 CONSORT diagram
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F IGURE 2 Representation of the
chronoIFLO5 protocol. Irinotecan was
administered at only one of the six time
points in each patient
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300 mg/sqm/day for leucovorin and 20 mg/sqm/day for
oxaliplatin.14 The treatments were administered on a full outpatient
basis through an ambulatory infusion pump allowing in time pro-
gramming and delivery of all the medications while the patient was
at her/his home (Melodie, Aguettant, France).16 Treatment courses
were repeated every 3 weeks, that is, after a 16-day chemotherapy-
free interval. No primary or secondary G-CSF prophylaxis was
allowed.
2.3 | Outcomes
Efficacy outcome measures included objective response rate,
which was calculated using the RECIST v1.1 criteria,14 and time-
to-event endpoints, which comprised progression-free survival
and overall survival. Clinical, haematological and biochemical toxic-
ity was graded before each chemotherapy cycle according to the
NCI CTC AE v2 criteria.14 Relative dose intensity was calculated as
the ratio between the actual dose (expressed in mg/sqm/week) of
the three cytotoxic drugs delivered over the whole treatment
duration and the theoretical full dose (60 mg/sqm/week for
irinotecan, 26.7 mg/sqm/week for oxaliplatin and 933.3 mg/sqm/
week for fluorouracil).14
2.4 | Statistical considerations
Efficacy and tolerability outcomes were evaluated separately in the
subgroups having received chronoIFLO5 as first- and second-line che-
motherapy. Descriptive only statistics were used to characterise the
TABLE 1 Clinical and demographical characteristics of the study population
First line (N = 149) Second line (N = 44)
All (N = 193)
Feature Median Range Median Range Median Range
Age (years) 61 29 to 80 62 34 to 79 61 29 to 80
N % N % N %
Gender
Males 97 65.1% 33 75.0% 130 67.4%
Females 52 34.9% 11 25.0% 63 32.6%
Performance status (WHO)
0 106 71.1% 36 81.8% 142 73.6%
1 36 24.2% 8 18.2% 44 22.8%
2 7 4.7% 0 0.0% 7 3.6%
Site of primary tumour
Colon 116 77.9% 33 75.0% 149 77.2%
Rectum 33 22.1% 11 25.0% 44 21.8%
Number of metastatic sites
1 68 45.6% 25 56.8% 93 48.2%
2 50 33.6% 13 29.5% 63 32.6%
3+ 31 20.8% 6 13.6% 37 19.2%
Organs involved
Liver only 54 36.2% 14 31.8% 68 35.2%
Liver + other 72 48.3% 16 36.4% 88 45.6%
Other only 23 15.4% 14 31.8% 37 19.2%
Synchronous metastases 111 74.5% 30 68.2% 141 73.1%
ALP > 300 IU/L 42 31.8% 7 17.9% 49 28.7%
WBC > 10 × 109/L 31 20.8% 5 11.6% 36 18.8%
Adjuvant chemotherapy 33 22.1% 9 20.5% 42 21.8%
Prior chemotherapy for metastatic diseasea
Fluoropyrimidine 41 93.2%
Oxaliplatin NA 20 45.5% NA
Irinotecan 13 29.5%
Other 5 11.4%
aMore than one drug per patient was possible.
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outcomes, and no comparative analysis was performed, given the
exploratory nature of this report. Time-to-event endpoints were
calculated from the day of randomisation up to that of progression
(for progression-free survival) or death (for overall survival). The most
recent date with valid follow-up data was used to censor non-
progressing or alive patients, respectively. The database was frozen in
May 2017.
3 | RESULTS
3.1 | Study population
Table 1 describes the main clinical and demographic features of
the 193 eligible patients, separately in the 149 patients treated in the
first-line setting (77.2%) and in the 44 patients having received the
chonomodulated triplet as a second-line treatment (22.8%) (Table 1).
The main reasons for discontinuing chronoIFLO5 included progressive
disease (N = 47; 24.4%), severe toxicity (N = 76; 39.3%), including two
toxic deaths (1.0%), patient refusal (N = 17; 8.8%) and surgery of
metastases (N = 22; 11.4%) (Figure 1).
All the 44 patients receiving chronoIFLO5 in the second-line
setting had displayed resistance to first-line treatment, with either
disease progression on first-line chemotherapy or early relapse
after completion of adjuvant chemotherapy. Additionally,
10 patients (22.7%) had also received prior adjuvant chemotherapy,
and 11 patients (25%) had received prior radiotherapy. Moreover,
41 patients (93.2%) had primary tumour resection, while metasta-
ses surgery had been performed for 21 patients (47.7%). Overall,
the vast majority of the patients had been exposed to folinate-
modulated fluoropyrimidines, about half to oxaliplatin, and less
than a third to irinotecan (Table 1). Other uncommonly used drugs
in first-line treatment included carboplatin and mitomycin
C. Primary resistance to first-line treatment had occurred in
12 patients (27.3%). Median duration of first-line chemotherapy
was 5.5 months. Second-line chronoIFLO5 was started after a
median duration of 3.9 months after completion of first-line
chemotherapy.
3.2 | Chemotherapy
The 193 patients received a total of 1138 cycles: 905 (79.5%) as first-
line treatment and 233 (20.5%) as second-line treatment. The median
number of cycles per patient was 6 (range, 1 to 18) with frontline
chronoIFLO5, and 5 (1 to 12) when used as salvage protocol. At least
one dose reduction was necessary in 55% and 60% of the patients for
each of the three drugs, with a similar number of patients having
required at least one deferral of treatment for 5 or more days. The
proportions were similar in chemotherapy naïve or previously treated
patients (data not shown). Thus, median relative dose intensities of
each drug in the triplet were close to 90% in both first- and second-
line settings (Figure 3). Only about 5% of the patients had actual
relative dose intensities of less than 70% for each medication.
3.3 | Efficacy
Frontline chronoIFLO5 was associated with a median overall survival
of 19.9 months [95% CI: 15.4-24.5 months] (Figure 4A) and a median
progression-free survival of 8.7 months [7.5-9.9] (Figure 4C). Respec-
tive figures in the second-line setting were 16.3 months [11.8-20.8]
(Figure 4B) and 6.7 months [4.8-8.9] (Figure 4D). Two- and 5-year
overall survival rates were, respectively, 41.0% [36.9-45.1] and 16.6%
[13.3-19.9] with first-line chronoIFLO5, and 34.9% [27.6-42.2] and
8.4% [4.0-12.8] when chronoIFLO5 was given as rescue second-line
protocol (Figure 4A,B).
Complete and partial radiological responses were observed in six
and 80 patients, respectively, among the 138 evaluated patients on
first-line chronoIFLO5. This resulted in an objective response rate of
62.3% [54.2-70.4] (Figure 4E). Since 39 patients also had disease
stabilisation as best response, disease control rate was 90.6%
F IGURE 3 Boxplots of the relative
administered dose intensities of the three main
cytotoxics: irinotecan (left), oxaliplatin (centre)
and 5-fluorouracil (right), throughout the
whole study, separately in first-line (1L) and in
second-line (2L) settings
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[85.7-95.5]. Second-line chronoIFLO5 achieved one complete and
14 partial responses, and 15 disease stabilisations among 40 evaluated
patients. Thus, second-line chronoIFLO5 resulted in an objective
response rate of 37.5% [22.5-52.5] and a disease control rate of
75.0% [61.6-88.4] (Figure 4F). Disease progression occurred in
13 patients on first line and in 10 patients in second line.
3.4 | Safety
Overall, 58 individual serious adverse events took place in the whole
trial population, with 47 being considered possibly, probably or likely
caused by the administered chemotherapy. No unexpected serious
adverse event occurred, and a total of 40/43 (93.0%) and 14/15
(93.3%) events resulted in an unplanned admission, in first- and
second-line settings, respectively.
A total of two toxic deaths occurred in first-line treatment (1%).
One patient died with Grade 5 diarrhoea, and the other one with diges-
tive fistulisation. Protocol safety and authorisation to continue recruit-
ment was confirmed by an Independent Data Monitoring Committee at
an interim analysis after inclusion of the initial 100 patients.14
Out of the 149 patients receiving chronoIFLO5 as first-line treat-
ment, 36 (24.2%) experienced at least one severe or life-threatening
(Grade 3 or 4) toxicity. Diarrhoea (44.3%) was the most frequent clini-
cal toxicity, whereas neutropenia was the most common
haematological one, with very few febrile instances despite no G-CSF
prophylaxis (Table 2). The worst incidence of individual Grade 3-4 tox-
icity per cycle was 10.6% for diarrhoea, which was the most frequent
adverse event (Table 2).
Comparable toxicity patterns were observed in the patients
treated in the second-line setting, with 10 of 44 (22.7%) having
encountered at least one episode of severe toxicity. Similar to the
earlier disease setting, diarrhoea and neutropenia were the Grade
3-4 toxicities with the highest incidence per patient or per cycle
(Table 2).
3.5 | Subsequent treatments
After this triplet chronomodulated protocol, investigators had no
restriction in the choice of subsequent chemotherapy drugs or
regimens, if they felt further treatment was indicated.
F IGURE 4 Main efficacy outcomes in patients receiving chronoIFLO5 as first-line (left panels A, C, E) or as second-line (right panels B, D, F)
protocol. Kaplan-Meier curves depicting overall survival (panels A, B) and progression-free survival (panels C, D) durations, and waterfall plots
showing best objective response (panels E, F)
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At least one additional chemotherapy protocol was administered
to 117 (78.5%) and 38 (86.4%) patients after first- or second-line
chronoIFLO5, respectively. Given the strict rules for protocol with-
drawal for toxicity (ie, two episodes of severe toxicity despite dose
reduction), a total of 67 (34.4%) patients continued the chro-
nomodulated triplet outside the study protocol, with further dose
reductions performed at the discretion of the lead clinician. Furtherly
given drugs included mitomycin C, cetuximab, capecitabine,
bevacizumab and carboplatin, alongside the rechallenge with either
irinotecan- or oxaliplatin-based regimens. Six patients (3%) received
hepatic artery infusion protocols, and a total of 95 (48.7%) patients
received further chronomodulated chemotherapy.
A total of 22 patients underwent metastases resection after
having received chronoIFLO5, 20 (13.4%) as first-line and 2 (4.5%)
as second-line (Figure 2) treatment. The majority of resections
involved the liver (N = 20), and in two cases included also re-
section of the primary tumour alongside the liver. Additionally for
one patient, each surgery was performed only on the pulmonary or
the nodal disease. Thus, secondary hepatic surgery of initially
unresectable disease was performed in 29.4% of the 68 patients
with liver-only metastases (Table 1). The 22 patients with down-
sized and then resected metastatic disease presented a median OS
of 58.3 [37.9-78.6] months.
4 | DISCUSSION
In this time-finding European prospective study, we observed rather
favourable profiles of both antitumour efficacy and safety of the chro-
nomodulated triplet combination of irinotecan, oxaliplatin and
fluorouracil-leucovorin administered every 21 days, either as frontline
or as rescue treatment of metastatic colorectal adenocarcinoma. Our
observations are based on unplanned descriptive analyses, exploring
the outcomes separately in first- and second-line.
In both settings, half of the patients received relative dose inten-
sities of the order of at least 90% (Figure 3) and five or more cycles,
assuring therefore satisfactory balance between adequate treatment
intensity and duration for most patients. This converted consequently
into promising objective response rate and progression-free survival
outcomes (Figure 4C-F).
In the first-line setting, these results compare favourably with lit-
erature reports in multicentre trials with conventional triplet regimens
of the same drugs, FOLFIRINOX (irinotecan, fluorouracil, leucovorin,
oxaliplatin) or FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and
irinotecan),17-19 and even more so with less successful combination
schedules.20-23 Similarly favourable appears the overall tolerability of
frontline chronoIFLO5 (Table 2) comparatively to literature data.20-23
Moreover, although the current study was performed before molecu-
lar selection and targeted treatments became widely implemented,24
the overall survival observed here (Figure 4A) is of the same order of
magnitude as that in the most recent studies conducted in metastatic
colorectal cancer.2
In the second-line setting, limited evidence currently exists for
the triplet combination, beside small single-institution studies.11,25,26
Although the various schedules were reported altogether to be feasi-
ble and active, chronoIFLO511 was the only one to be tested prospec-
tively in an international setting as salvage regimen in pretreated
patients with metastatic colorectal cancer, albeit as an exploratory
outcome of a tolerance-based study. Indeed, there is concern about
the risk of poor tolerance to the triplet regimen, even as frontline




patient (N = 149)
Per
cycle (N = 905)
Per
patient (N = 44)
Per
cycle (N = 233)
Toxicity N % N % N % N %
Haematological
Neutropenia 21 14.6% 32 3.5% 12 27.3% 30 12.9%
Febrile neutropenia 3 2.1% 3 0.3% 0 0% 0 0%
Anaemia 6 4.2% 14 1.5% 1 2.3% 4 1.7%
Thrombocytopenia 3 2.1% 5 0.6% 1 2.3% 1 0.4%
Clinical
Diarrhoea 66 44.3% 96 10.6% 16 36.4% 22 9.4%
Nausea 26 17.4% 38 4.2% 9 20.5% 9 3.9%
Vomiting 23 15.4% 33 3.6% 6 13.6% 9 3.9%
Asthenia 22 14.8% 29 3.2% 3 6.8% 3 1.3%
Mucositis 9 6.0% 10 1.1% 2 4.5% 2 0.9%
Sensory neuropathy 5 3.4% 5 0.6% 2 4.5% 4 1.7%
Hand-foot
syndrome
0 0% 0 0% 0 0% 0 0%
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treatment; hence, the scarce experience reported and the preference
for doublet combination.27 Nonetheless, the activity of second-line
doublets after failure of the other appears substantially lower than
that observed in our study28,29 (Figure 4B,D,F). However, targeted
agents against EGFR or VEGF, in selected populations, meaningfully
improved antitumour activity of the doublet combinations in this con-
text.29,30 Interestingly, monoclonal antibodies added to first-line trip-
let, chronomodulated or conventional, also displayed significantly
better outcomes.10,31,32 Second-line chronomodulated triplet could
further be associated with the appropriate targeted agent thus
enhancing efficacy in chemorefractory disease.13,33 In case of contra-
indication to the use of anti-EGFR or anti-VEGF agents, second-line
triplet combination could offer nonetheless arguably the highest sal-
vage activity, especially in candidates for an onco-surgical strategy.34
Although this was a time-finding study in a cohort of unselected
patients for oncosurgical strategy, the secondary resection rate in
patients with liver-only disease observed here (29.4%) compares
favourably with more recent pooled evidence on downsizing systemic
chemotherapy and rescue liver surgery in patients with initially
unresectable colorectal liver metastases.3 Moreover, the median sur-
vival of the subgroup of patients undergoing secondary surgery after
chronoIFLO5 approached 5 years, suggesting a long-lasting control of
the disease by this combinational chronomodulated regimen. A dedi-
cated, prospective evaluation of this triplet is warranted to confirm
our findings within an onco-surgical strategy setting.
ChronoIFLO5 confirmed in this international setting an altogether
satisfactory tolerance, especially concerning hematotoxicity rates
among the lowest ones in the literature without primary G-CSF pro-
phylaxis (Table 2) for such highly effective triplet regimens.17-23 For
instance, a previous trial with conventional triplet reported an inci-
dence of Grades 3 and 4 neutropenia of 50%, with 5% instances of
febrile neutropenia.18 Our findings here support prior evidence of a
much lower neutropenia incidence with chronomodulated chemother-
apy in comparison with conventional administration.35 Hence,
chronoIFLO5 could be regarded as a possible fully-ambulatory admin-
istration schedule of the triplet in those patients with poor tolerance
to conventional delivery, as well as in other clinical scenarios where
the triplet administration is an available therapeutic option, such as
pancreatic ductal adenocarcinoma, or even biliary tract and gastric
adenocarcinomas.36-38
There is evidence suggesting that circadian-based treatment admin-
istration of anticancer drugs could be further optimised to provide sup-
plementary benefit when individual biological clock features are taken
into account.8 In particular, for this triplet combination, adaptation of the
timing of administration of irinotecan differently in women (afternoon)
and men (morning) could lead to an additional reduction in adverse
events without impact on antitumour activity.14 Interestingly, neutrope-
nia and appetite loss are two of the toxicities most affected by gender-
specific circadian refinement,8,14 and also two surrogate adverse events
of suboptimal chronotherapy delivery.8 Moreover, chronomodulated
chemotherapy delivered completely at the patient's home with dedicated
infusional pumps can benefit from integrative solutions of digital multi-
dimensional remote surveillance of physiology and behaviour, whose
feasibility and clinical relevance has been demonstrated expressly with
this triplet regimen.39 This provides a novel opportunity of an adaptive
closed-loop control of cytotoxic drug administration based on patient-
generated data, unique to the fully-ambulatory schedule.16
We acknowledge the limitations of our study in the current era of
precision oncology, since the recruitment and treatment occurred
when molecular genotype and phenotype or sideness had not yet
been identified as relevant factors for treatment selection. Moreover,
the time-finding primary endpoint of the trial was toxicity based;
hence, the efficacy outcomes presented here remain exploratory in
nature.
Intriguingly, a lower incidence of severe diarrhoea appeared to
occur with chronoIFLO5 in second-line compared to first-line treat-
ment (Table 2), despite similar doses used regardless of the setting.
Although more careful patient selection could have accounted for this
difference, a potential adaptation of the digestive mucosa or of the
intestinal microbiota40 to toxicity and/or of the patient's behaviour rel-
atively to chemotherapy administration, diet and support medications
could have also played a role.
In conclusion, although this international trial did not meet its
primary endpoint of identifying the least toxic administration time
of irinotecan, it provided prospective validation of the safety and
efficacy of the chronomodulated combination of irinotecan,
oxaliplatin and leucovorin-fluorouracil administered at the patient's
home. The clinical evidence reported here is the first on a multi-
centre basis to support the consideration of this triplet combination
as an upfront and salvage regimen for patients with metastatic colo-
rectal cancer.
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